Trials / Completed
CompletedNCT02139189
Restore Myocardial Function With CorMatrix® ECM® Particulate (P-ECM)
RESTORE Myocardial Function With CorMatrix® ECM® Particulate (P-ECM) Implantation in Subjects With LVEF 25 to 40% Study
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 9 (actual)
- Sponsor
- Corvivo Cardiovascular, Inc. · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this CorMatrix P-ECM safety and feasibility study is to evaluate the safety and functional effect of the CorMatrix P-ECM.
Detailed description
Evaluate the safety of the CorMatrix ECM Particulate (P-ECM) delivered trans-epicardially to subjects with left ventricular ejection fraction (LVEF) 25 to 40% during coronary artery bypass grafting (CABG)
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DEVICE | P-ECM Implant | P-ECM Implant into damaged ischemic and/or infarcted myocardium |
Timeline
- Start date
- 2014-06-01
- Primary completion
- 2016-01-01
- Completion
- 2016-01-01
- First posted
- 2014-05-15
- Last updated
- 2017-07-19
Locations
1 site across 1 country: Poland
Source: ClinicalTrials.gov record NCT02139189. Inclusion in this directory is not an endorsement.